| Product specifications |
Information source:
Vendor
Last updated: Oct. 11, 2021 |
| General | |
|---|---|
| Product name | AIRAscore structure |
| Company | AIRAmed |
| Subspeciality | Neuro |
| Modality | MR |
| Disease targeted | Neurodegenerative diseases, e.g. dementia, Alzheimer’s disease, multiple sclerosis, Parkinson’s Disease |
| Key-features | Brain tissue and anatomy segmentation, volume quantification, normative comparison, report generation, WMH detection and quantification |
| Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) |
| Data characteristics | |
| Population | All with suspicion of or in treatment of neurodegenerative disease |
| Input | 3DT1 MRI, 3D or 2D T2 FLAIR, 1.5 or 3T |
| Input format | DICOM |
| Output | Table of quantified values, bar charts and a pictogram-based spatial representation of the values, PDF-report, segmentation overlays |
| Output format | DICOM, DICOM-PDF |
| Technology | |
| Integration | Integration in standard reading environment (PACS) |
| Deployment | Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution |
| Trigger for analysis | On demand, triggered by a user through e.g. a button click, image upload, etc. |
| Processing time | 1 - 10 minutes |
| Certification | |
|
CE
|
Certified,
Class I
, MDD
|
|
FDA
|
No or not yet |
| Market presence | |
| On market since | 08-2020 |
| Distribution channels | |
| Countries present (clinical, non-research use) | |
| Paying clinical customers (institutes) | |
| Research/test users (institutes) | |
| Pricing | |
| Pricing model | Pay-per-use |
| Based on | Number of analyses |
| Evidence | |
| Peer reviewed papers on performance | |
| Non-peer reviewed papers on performance | |
| Other relevant papers | |